MOTS-c Research: Mitochondrial Peptide Data

Summary

MOTS-c is a 16–amino-acid peptide encoded within the mitochondrial 12S rRNA gene — one of the first recognised mitochondrial-derived peptides. Research links it to AMPK activation, metabolic flexibility and exercise adaptation. Nearly all functional data comes from cell and rodent work; human research is observational.

Last reviewed 2026-09-01

What it is

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a short peptide transcribed from mitochondrial DNA rather than the nuclear genome, placing it in the class of mitochondrial-derived peptides alongside humanin.

Identified in 2015 by a research group at the University of Southern California while scanning mitochondrial DNA for unannotated open reading frames.

Endogenous, encoded in mitochondrial DNA. Circulating levels have been reported to decline with age and to rise acutely with exercise.

It reframed mitochondria as signalling organelles that send peptide messages to the nucleus, and it was reported to prevent diet-induced obesity and insulin resistance in mice.

How it works

In plain terms

MOTS-c acts as a message from the mitochondria to the rest of the cell, nudging it toward burning fuel more efficiently — a signal similar to what exercise and fasting produce.

Technical detail

MOTS-c inhibits the folate–methionine cycle, causing accumulation of AICAR, which activates AMPK. Under metabolic stress it translocates to the nucleus and binds regulatory regions of stress-response genes, including antioxidant response element (ARE) sites, acting with NRF2. Downstream effects reported include increased glucose uptake, improved insulin sensitivity and enhanced fatty acid oxidation in skeletal muscle.

Pathways involved

Folate cycle inhibition → AICAR accumulation → AMPK activation
Nuclear translocation and ARE/NRF2-linked gene regulation
Skeletal muscle glucose uptake and insulin sensitivity
Fatty acid oxidation and metabolic flexibility

Current research

Laboratory research

Cell studies demonstrate AMPK activation and increased glucose uptake in myotubes, and nuclear localisation under metabolic stress.

Animal research

Mouse studies report prevention of diet-induced obesity, improved insulin sensitivity, restored exercise capacity in aged animals and reduced age-related weight gain. Effects are generally larger in metabolically stressed animals than in healthy ones.

Human research

Human work is largely observational: circulating MOTS-c rises after acute exercise, is lower in individuals with insulin resistance, and a mitochondrial DNA variant affecting MOTS-c has been associated with differences in type 2 diabetes risk in some Japanese cohorts. No interventional human trials have been published.

Ongoing research

Interventional human data remains the main gap; check registries for any current entries.

What is being investigated

Insulin sensitivity and glucose handling in rodent models
Diet-induced obesity prevention in mice
Exercise capacity and skeletal muscle adaptation
Age-associated metabolic decline
Mitochondrial-to-nuclear stress signalling

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

No interventional human trials exist in any indication
Rodent metabolic findings frequently fail to translate to humans
Chronic AMPK-axis manipulation has unknown long-term consequences
Human dosing, route and pharmacokinetics uncharacterised
Not an approved medicine anywhere

Evidence ratings

Laboratory studies

Strong

AMPK and folate-cycle mechanism well characterised in vitro.

Animal studies

Moderate

Reproducible metabolic effects in mice, mostly under stress conditions.

Human studies

Limited

Observational associations only; no interventional trials.

Long-term safety

None

No human exposure data.

Comparisons

MOTS-c vs SS-31

Signalling peptide versus cardiolipin-targeted mitochondrial peptide.

Verified peptide suppliers

References

[1]MOTS-c — indexed literature — PubMed, 2015–present
[2]MOTS-c, AMPK and metabolic homeostasis — PubMed, 2015–present
[3]Mitochondrial-derived peptides and exercise — PubMed, 2018–present
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is MOTS-c?+

A 16–amino-acid peptide encoded in mitochondrial DNA that appears to act as a metabolic signal between mitochondria and the nucleus.

How does MOTS-c work?+

It inhibits the folate cycle, leading to AICAR accumulation and AMPK activation, and can move into the nucleus to influence stress-response gene expression.

Is MOTS-c produced naturally?+

Yes — it is endogenous, encoded within the mitochondrial 12S rRNA gene.

Does exercise raise MOTS-c?+

Human observational studies report acute increases in circulating MOTS-c after exercise, particularly in skeletal muscle.

Is MOTS-c FDA approved?+

No. There are no approved MOTS-c products and no completed interventional human trials.

Is MOTS-c an exercise mimetic?+

It is sometimes described that way because it activates AMPK, the same energy sensor exercise activates, but no human study has tested that claim.

What is a mitochondrial-derived peptide?+

A peptide encoded in mitochondrial rather than nuclear DNA. Humanin and the SHLP family are other examples.

Does MOTS-c decline with age?+

Reported circulating levels are lower in older individuals in several observational datasets, though methodology for measuring it is not standardised.

Continue your research

SS-31 research

Mitochondrial function explained

Metabolic health